Table A2.
Example of GReFO recommendations monitoring for GdP Toracic year 2019—Lung NSLC.
| Consumption Index | Number of Patients Treated in I.R.S.T. | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Molecule | Recommendation | Expected Cases Consumption Index Forecast for Emilia Romagna Territories | Note | per 100,000 Inhabitants Planned by GReFO |
Planned for Territory of Forlì-Cesena | Forlì- Cesena | Romagna | Extra Romagna | Evaluation |
| Durvalumab | Strong positive | 140 | Consolidation after chemoradiotherapy in pts non in PD con PDL1 ≥ 1% |
3.1 | 12 | 3 | 1 | 0 | Compliant |
| Pembrolizumab | Strong positive | 300 | I line PD-L1 ≥ 50%—non sq/sq | 6.7 | 27 | 19 | 10 | 6 | Compliant |
| Pembrolizumab + Pemetrexed + CDDP | Strong positive | 600 | I line PD-L1 < 50% o non noto NON SQ | 13.5 | 53 | 0 | 0 | 0 | Compliant |
| Pembrolizumab | Weak positive | 540 | II line WT (indipendent from histology) | 12.1 | 48 | 3 | 2 | 1 | Compliant |
| Nivolumab | Weak positive | 12 | 0 | 2 | Compliant | ||||
| Atezolizumab | Weak positive | 20 | 3 | 11 | Compliant | ||||
| Afatinib/Erlotinib/Gefinitib | Weak negative | 35 | NSCLC I line EGFR + | 0.8 | 3 | 6 | 1 | 0 | Not Compliant |
| Osimertinib | Strong positive | 140 | NSCLC I line EGFR + | 3.1 | 12 | 6 | 4 | 2 | Compliant |
| Nintedanib + Docetaxel | Weak negative | 180 | NSCLC II line WT | 4.0 | 16 | 0 | 0 | 0 | Compliant |
| Pemetrexed | Weak positive | NSCLC II line WT | 3 | 0 | 2 | Compliant | |||
| Docetaxel | Weak/strong negative | NSCLC + SCLC II line WT | 8 | 4 | 3 | Compliant | |||
| Erlotinib | NA | NSCLC + SCLC II line WT | 0 | 0 | 0 | Compliant | |||
| Osimertinib | Strong positive | 60 | NSCLC II line EGFR +, T790M + |
1.3 | 5 | 2 | 0 | 0 | Compliant |
| Docetaxel/TKI | 50 | NSCLC II line EGFR +, T790M not changed |
1.1 | 4 | 1 | 0 | 1 | Compliant | |
| Ceritinib | Weak negative | 3 | NSCLC I line ALK + | 0.1 | 0 | 0 | 0 | 0 | Compliant |
| Ceritinib | Weak positive | 20 | NSCLC II line ALK + | 0.4 | 2 | 0 | 0 | 0 | Compliant |
| Crizotinib | Weak negative | 3 | NSCLC I line ALK + | 0.1 | 0 | 0 | 0 | 0 | Compliant |
| Crizotinib | Strong/Weak positive | 12 | NSCLC I line ROS-1 + | 0.3 | 1 | 1 | 0 | 0 | Compliant |
| Alectinib | Strong positive | 52 | NSCLC I Line ALK + | 1.2 | 5 | 0 | 1 | 0 | Compliant |
| Alectinib | Weak positive | 20 | NSCLC II line ALK + | 0.4 | 2 | 2 | 0 | 0 | Compliant |
| Docetaxel/doppietta platino | 0 | NSCLC II line ALK + | 0.0 | 0 | 0 | 0 | 0 | Compliant | |
| Dabrafenib/trametinib | NA | / | NSCLC Braf V600+ | ||||||